O RH CS THE Applicant:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Michael PATANE

Attorney Docket No.: CASM122095

Application No.: 10/734,721

Filed: Title:

December 11, 2003 YEAST TREATMENT

INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101 March 31, 2004

TO THE COMMISSIONER FOR PATENTS:

Applicant is aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

- 1. X Copies of the listed patents, publications, and other information are enclosed for the Examiner's use.
- Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.
- 3. X The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 03-1740. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application. A copy of this document is enclosed.

Respectfully submitted,

CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLLC ,

Jary S Kindness

Registration No. 22,178

Direct Dial No. 206.695.1702

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Mail Stop Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date:

Date: March 31, 2004

GSK/PAS:bmc

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLIC 1420 Fifth Avenue Suite 2800 Seattle, Washington 98101 206.682.8100



ı		PROSECUTION	ON OF	THE	SUBJECT API	<u>PLICATION</u>		
Applicant:		Michael PATAN	Е		Attorney Doc	ket No. CASM1220	95	
Application	No.:	10/734,721			Group Art Un	it:		
Filed:		December 11, 20	03					
Title:		YEAST TREAT	MENT					
		<u>U</u> .	S. PA	<u> TENT</u>	DOCUMENTS	<u>S</u>		
*Examiner Initials	Cite No.	Document No		nd ode	Date (mm/dd/yyyy)	Name		
Non	e							
		<u>FOR</u>	EIGN I	PATE	NT DOCUMEN	<u>NTS</u>		
*Examiner Initial	Cite No.	Document No.	Kind Code		cation Date n/dd/yyyy)	Country	English Abstract Provided	Translation Provided
	F1	WO 95/31183	A1	11.	/23/1995	WIPO		
					ORMATION Date, Pertinent 1	Pages, Etc.)		
*Examiner Initial	Cite No.		.					

 O1	Allshire, R.C., "Introduction of Large Linear Minichromosomes into <i>Schizosaccharomyces Pombe</i> by an Improved Transformation Procedure", Genetics, 87:4043-4047, June 1990.
 O2	Anzai, K., et al., "Frequent Fusion of Liposomes to a Positively Charged Planar Bilayer without Calcium Ions", J. Biochem., 114(4):487-191, 1993.
 О3	Li, W.M., et al., "Intermembrane Transfer of Polyethylene Glycol-Modified Phosphatidylethanolamine as a Means to Reveal Surface-Associated Binding Ligands on Liposomes", Biochimica et Biophysica Acta, 2001, pp. 193-206.
 O4	Miller, C.R., et al., "Liposome-Cell Interactions in Vitro: Effect of Liposome Surface Charge on the Binding and Endocytosis of Conventional and Sterically Stabilized Liposomes", Biochemistry, 37:12875-12883, 1998.

LAW OFFICES OF CHRISTENSEN O'CONNOR JOHNSON KINDNESSPLIC 1420 Fifth Avenue Suite 2800 Seattle, Washington 98101 206.682.8100

O5	Perrie, Y., et al., "Liposome-Mediated DNA Vaccination: The Effect of Vesicle Composition", Vaccine, 19:3301-3310, 2001.
O6	Stamatatos, L. et al., "Interactions of Cationic Lipid Vesicles with Negatively Charged Phospholipid Vesicles and Biological Membranes", Biochemistry, 27:3917-3925, 1988.
Examiner	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

GSK/PAS:bmc